A detailed history of Park Avenue Securities LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Park Avenue Securities LLC holds 2,391 shares of ALNY stock, worth $1.07 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,391
Previous 2,731 12.45%
Holding current value
$1.07 Million
Previous $1.25 Million 23.61%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 05, 2026

SELL
$423.47 - $491.22 $143,979 - $167,014
-340 Reduced 12.45%
2,391 $951,000
Q3 2025

Oct 23, 2025

BUY
$311.12 - $482.13 $200,983 - $311,455
646 Added 30.98%
2,731 $1.25 Million
Q2 2025

Jul 14, 2025

BUY
$224.32 - $326.09 $467,707 - $679,897
2,085 New
2,085 $680,000
Q4 2024

Jan 14, 2025

BUY
$232.27 - $300.43 $124,961 - $161,631
538 Added 64.82%
1,368 $322,000
Q3 2024

Oct 03, 2024

BUY
$233.81 - $287.01 $194,062 - $238,218
830 New
830 $228,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $55.3B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Park Avenue Securities LLC Portfolio

Follow Park Avenue Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Park Avenue Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Park Avenue Securities LLC with notifications on news.